Literature DB >> 35922514

RNA editing underlies genetic risk of common inflammatory diseases.

Stephen B Montgomery1,2, Jin Billy Li3, Qin Li1, Michael J Gloudemans2,4, Jonathan M Geisinger1, Boming Fan5, François Aguet6, Tao Sun1, Gokul Ramaswami1, Yang I Li1,7, Jin-Biao Ma5, Jonathan K Pritchard1,8.   

Abstract

A major challenge in human genetics is to identify the molecular mechanisms of trait-associated and disease-associated variants. To achieve this, quantitative trait locus (QTL) mapping of genetic variants with intermediate molecular phenotypes such as gene expression and splicing have been widely adopted1,2. However, despite successes, the molecular basis for a considerable fraction of trait-associated and disease-associated variants remains unclear3,4. Here we show that ADAR-mediated adenosine-to-inosine RNA editing, a post-transcriptional event vital for suppressing cellular double-stranded RNA (dsRNA)-mediated innate immune interferon responses5-11, is an important potential mechanism underlying genetic variants associated with common inflammatory diseases. We identified and characterized 30,319 cis-RNA editing QTLs (edQTLs) across 49 human tissues. These edQTLs were significantly enriched in genome-wide association study signals for autoimmune and immune-mediated diseases. Colocalization analysis of edQTLs with disease risk loci further pinpointed key, putatively immunogenic dsRNAs formed by expected inverted repeat Alu elements as well as unexpected, highly over-represented cis-natural antisense transcripts. Furthermore, inflammatory disease risk variants, in aggregate, were associated with reduced editing of nearby dsRNAs and induced interferon responses in inflammatory diseases. This unique directional effect agrees with the established mechanism that lack of RNA editing by ADAR1 leads to the specific activation of the dsRNA sensor MDA5 and subsequent interferon responses and inflammation7-9. Our findings implicate cellular dsRNA editing and sensing as a previously underappreciated mechanism of common inflammatory diseases.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35922514     DOI: 10.1038/s41586-022-05052-x

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  83 in total

1.  RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself.

Authors:  Brian J Liddicoat; Robert Piskol; Alistair M Chalk; Gokul Ramaswami; Miyoko Higuchi; Jochen C Hartner; Jin Billy Li; Peter H Seeburg; Carl R Walkley
Journal:  Science       Date:  2015-07-23       Impact factor: 47.728

Review 2.  The role of regulatory variation in complex traits and disease.

Authors:  Frank W Albert; Leonid Kruglyak
Journal:  Nat Rev Genet       Date:  2015-02-24       Impact factor: 53.242

Review 3.  Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses.

Authors:  Charles E Samuel
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

Review 4.  A-to-I RNA editing - immune protector and transcriptome diversifier.

Authors:  Eli Eisenberg; Erez Y Levanon
Journal:  Nat Rev Genet       Date:  2018-08       Impact factor: 53.242

Review 5.  Functions and regulation of RNA editing by ADAR deaminases.

Authors:  Kazuko Nishikura
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

6.  Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature.

Authors:  Gillian I Rice; Paul R Kasher; Gabriella M A Forte; Niamh M Mannion; Sam M Greenwood; Marcin Szynkiewicz; Jonathan E Dickerson; Sanjeev S Bhaskar; Massimiliano Zampini; Tracy A Briggs; Emma M Jenkinson; Carlos A Bacino; Roberta Battini; Enrico Bertini; Paul A Brogan; Louise A Brueton; Marialuisa Carpanelli; Corinne De Laet; Pascale de Lonlay; Mireia del Toro; Isabelle Desguerre; Elisa Fazzi; Angels Garcia-Cazorla; Arvid Heiberg; Masakazu Kawaguchi; Ram Kumar; Jean-Pierre S-M Lin; Charles M Lourenco; Alison M Male; Wilson Marques; Cyril Mignot; Ivana Olivieri; Simona Orcesi; Prab Prabhakar; Magnhild Rasmussen; Robert A Robinson; Flore Rozenberg; Johanna L Schmidt; Katharina Steindl; Tiong Y Tan; William G van der Merwe; Adeline Vanderver; Grace Vassallo; Emma L Wakeling; Evangeline Wassmer; Elizabeth Whittaker; John H Livingston; Pierre Lebon; Tamio Suzuki; Paul J McLaughlin; Liam P Keegan; Mary A O'Connell; Simon C Lovell; Yanick J Crow
Journal:  Nat Genet       Date:  2012-09-23       Impact factor: 38.330

7.  Isoforms of RNA-Editing Enzyme ADAR1 Independently Control Nucleic Acid Sensor MDA5-Driven Autoimmunity and Multi-organ Development.

Authors:  Kathleen Pestal; Cory C Funk; Jessica M Snyder; Nathan D Price; Piper M Treuting; Daniel B Stetson
Journal:  Immunity       Date:  2015-11-17       Impact factor: 31.745

Review 8.  Where Are the Disease-Associated eQTLs?

Authors:  Benjamin D Umans; Alexis Battle; Yoav Gilad
Journal:  Trends Genet       Date:  2020-09-07       Impact factor: 11.639

9.  The RNA-editing enzyme ADAR1 controls innate immune responses to RNA.

Authors:  Niamh M Mannion; Sam M Greenwood; Robert Young; Sarah Cox; James Brindle; David Read; Christoffer Nellåker; Cornelia Vesely; Chris P Ponting; Paul J McLaughlin; Michael F Jantsch; Julia Dorin; Ian R Adams; A D J Scadden; Marie Ohman; Liam P Keegan; Mary A O'Connell
Journal:  Cell Rep       Date:  2014-11-13       Impact factor: 9.423

10.  Limited statistical evidence for shared genetic effects of eQTLs and autoimmune-disease-associated loci in three major immune-cell types.

Authors:  Sung Chun; Alexandra Casparino; Nikolaos A Patsopoulos; Damien C Croteau-Chonka; Benjamin A Raby; Philip L De Jager; Shamil R Sunyaev; Chris Cotsapas
Journal:  Nat Genet       Date:  2017-02-20       Impact factor: 38.330

View more
  1 in total

Review 1.  RNA modifications: importance in immune cell biology and related diseases.

Authors:  Lian Cui; Rui Ma; Jiangluyi Cai; Chunyuan Guo; Zeyu Chen; Lingling Yao; Yuanyuan Wang; Rui Fan; Xin Wang; Yuling Shi
Journal:  Signal Transduct Target Ther       Date:  2022-09-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.